

Application No. 10/666,428
Amendment dated November 9, 2006
Reply to Office Action of August 9, 2006

AMENDMENTS TO THE DRAWINGS:

The attached sheets of drawings include changes to Figs. 4 and 6. These sheets, which include Figs 4 and 6, replace the original sheets including Figs. 4 and 6.

Attachment: Replacement Sheets
Annotated Sheets Showing Changes

REMARKS

Status Of Application

Claims 1-48 are pending in the application; the status of the claims is as follows:

Claims 2 and 38 are objected to because of the use of "The optimal settings".

Claims 5, 18, and 29 are objected to because the wording of the claim is unclear.

Claims 11, 24, 35, and 47 are objected to because of the use of "the components".

Claims 12, 25, 36, and 48 are not fully understood because of the objection to claim 11.

Claims 1, 9, 11, 13-15, 22, 26, 32, 33, 37, and 45 are rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 4,592,349 to Bird ("Bird Patent").

Claims 8, 10, 21, 23, 32, 34, 44, and 46 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird ("Bird Patent").

Claims 3, 4, 6, 16, 17, 19, 27, 28, 30, 39, 40, and 42 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird ("Bird Patent") in view of U.S. Patent No. 6,581,596 to Truitt ("Truitt Patent").

Claims 7, 20, 32, and 43 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird ("Bird Patent") in view of U.S. Patent No. 5,277,175 to Riggs et al. ("Riggs Patent").

Claims 5, 18, 29, and 41 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird ("Bird Patent") in view of U.S. Patent Publication No. 2003/0121517 A1 to McFarland, Jr. ("McFarland Publication").

Claims 11, 12, 24, 25, 35, 36, 47, and 48 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird ("Bird Patent") in view of U.S. Patent Publication No. 2005/0172954 A1 to Smith ("Smith Publication").

Claims 2 and 38 are rejected under 35 U.S.C. § 112, second paragraph, as failing to set forth the metes and bounds of the claim.

Information Disclosure Statement

Please note that an Information Disclosure Statement, along with a PTO Form 1449, is being filed concurrently herewith.

Specification

The Examiner has indicated an objection on the grounds that evacuation reservoir tube (48) is not mentioned in the specification but is shown in figure 6. However, the last sentence of paragraph 0041 states that "Evacuation reservoir 49 connects to forward apertures 15 by means of evacuation reservoir tube 48." Thus it appears that evacuation reservoir tube (48) has been mentioned in the specification. Applicant requests that the Examiner call Applicant's attorney if Examiner's objection has not been satisfied.

The Examiner has indicated an objection on the grounds that ventilator circuit Y patient connector (47) is not mentioned in the specification but is shown in figure 7. Applicant has amended paragraph 0044 of the specification such that it describes ventilator circuit Y patient connector (47). It is believed that this amendment satisfies the Examiner's objection.

Drawings

The Examiner has indicated an objection to the drawings on the grounds that the reference character "5" has been used to designate multiple elements; specifically a "connector tee" in Figure 1 and an "injector nozzle" in Figure 4. The use of reference

character "5" to refer to the injector nozzle in Figure 4 was an error. As can be seen in Figure 2, the injector nozzle in Figure 4 should be labeled with reference character "13." A revised Figure 4 showing the correction is submitted herewith.

The Examiner has indicated an additional objection to the drawings on the grounds that Figure 6 does not show a "Tube" (39) as described in the specification. The reference character 39 was inadvertently omitted from Figure 6. A revised Figure 6 including reference character 39 is submitted herewith.

Claim Amendments

Claim 1 has been amended to more particularly point out and distinctly claim the subject matter contained therein.

Claims 1, 13, 14, 26 and 37 have been amended to remove a comma.

Claim 26 has been amended to add the language clarifying that the claimed at least one aperture is open to the ambient to allow ingress and egress of flow. This language parallels language already included in the remaining independent claims.

Claims 2 and 38 have been amended to more particularly point out and distinctly claim the subject matter contained therein.

Claims 2, 5, 11, 12, 18, 24, 25, 29, 35, 36, 38, 47 and 48 have been amended as detailed below to respond to the Examiner's objections. These changes are not necessitated by the prior art, are unrelated to the patentability of the invention over the prior art, and do not introduce any new matter.

Objection to Claims

Applicant has amended claims 2 and 38 to add antecedent basis for the term “the optimal settings.” Thus, it is believed that the Examiner’s objection to these claims is now moot.

Applicant has amended claims 5, 18, and 29 to agree with the Examiner’s understanding of those claims and to make the wording of the claims clear. Thus, it is believed that the Examiner’s objection to these claims is now moot.

Applicant has amended claims 11, 24, 35, and 47 to remove reference to “the components” and to list the specific elements that “the components” referred to. Thus, it is believed that the Examiner’s objection to these claims is now moot.

The Examiner indicated an objection to claims 12, 25, 36, and 48 in light of the objection to claims 11, 24, 35, and 47. In light of Applicant’s amendments to claims 11, 24, 35, and 47, it is believed that the objection to claims 12, 25, 36, and 48 is now moot. However, Applicant has amended claims 12, 25, 36, and 48 to remove the term “means of identification” and to replace it with “identification device” as “identification device” is believed to be clearer in light of the claims from which claims 12, 25, 36, and 48 depend.

Accordingly, it is respectfully requested that the objection to claims 2, 5, 11, 12, 18, 24, 25, 29, 35, 36, 38, 47, and 48, be reconsidered and withdrawn.

No New Matter

This Amendment is being presented promptly after the discovery of the need therefor. This Amendment does not affect the scope of the claims, does not introduce any new matter, does not present any new issue, does not require any additional search, and will not present an undue burden on the personnel of the Patent and Trademark Office. Accordingly, it is respectfully requested that the Amendment be entered in accordance with 37 C.F.R. § 1.312.

35 U.S.C. § 102(b) Rejection

The rejection of claims 1, 9, 11, 13-15, 22, 26, 32, 33, 37, and 45 under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 4,592,349 to Bird ("Bird"), is respectfully traversed based on the following.

The Examiner has asserted that the Bird reference discloses all of the elements of Applicant's claims 1, 9, 11, 13-15, 22, 26, 32, 33, 37, and 45. However, in light of Applicant's amendments to independent claims 1, 13, 14, 26, and 37, it should now be clear that the portions of Bird cited by the Examiner do not disclose certain claimed elements. Specifically, the Examiner has not pointed to any portion of Bird which discloses that the Applicant's claimed at least one aperture is "open to the ambient to allow ingress and egress of flow." Applicant concedes that, as previously written, it may not have been clear that the phrase "open to the ambient to allow ingress and egress of flow" was intended to refer to the claimed one or more apertures. As Applicant has now removed the comma which previously separated these phrases, this uncertainty should now be removed.

Turning to Bird, it is apparent that the apertures cited by the Examiner are not open to the ambient; in every case, there appears to be a valve blocking the path to the ambient. The presence of the valve precludes these apertures from being "open" to the ambient. For example, turning to Bird's columns 29 and 30 and figure 5 described therein (which include the portion of Bird cited by the Examiner as disclosing Applicant's "at least one aperture of predetermined size"), there appears to be only a few ports disclosed, none of which are open to the ambient. Specifically, there appears to be an exhalation valve assembly 438, which is in turn connected to a line 451 and a tube 468. Line 451 and tube 468 are in turn connected to other parts of Bird's apparatus, not to the ambient. Although there does appear to a gate 472 connected to tube 468, this port would not disclose Applicant's aperture because (1) it is not part of a shroud encasing a venturi, (2) the fact that it is a "gate" precludes it from being "open" to the ambient, and (3) it is described as a gate to "permit entrainment of ambient air when required." Thus, gate 472 is described as

being capable of ingress only whereas Applicant's one or more apertures are capable of ingress and egress. An additional "expiratory gate valve 461" is also provided by Bird. However, again it does not disclose Applicant's one or more apertures as it (1) is not part of a shroud encasing a venturi, (2) the fact that it is a "gate" precludes it from being "open" to the ambient, and (3) it is described as a gate to "through which gases can escape to the atmosphere." Thus, gate 461 is described as being capable of egress only whereas Applicant's one or more apertures are capable of ingress and egress.

Thus, Bird fails to disclose Applicant's limitation of "at least one aperture of predetermined size, open to the ambient to allow ingress and egress of flow." This feature is included in each of independent claims 1, 13, 14, 26, and 37 (all as amended). As such, Bird fails to disclose all of the limitations of these claims as well as those that depend therefrom and is insufficient to form the basis of a rejection under 35 U.S.C. §102(b).

Accordingly, it is respectfully requested that the rejection of claims 1, 9, 11, 13-15, 22, 26, 32, 33, 37, and 45 under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 4,592,349 to Bird, be reconsidered and withdrawn.

35 U.S.C. § 103(a) Rejection

The rejection of claims 8, 10, 21, 23, 32, 34, 44, and 46 under 35 U.S.C. § 103(a), as being unpatentable over U.S. Patent No. 4,592,349 to Bird, is respectfully traversed based on the following.

As discussed above, Bird fails to disclose each and every element of independent claims 1, 13, 14, 26 and 37 from which claims 8, 10, 21, 23, 32, 34, 44, and 46 depend respectively. As such, these claims cannot be obvious in light of Bird. *Application of Glass*, 472 F.2d 1388 (C.C.P.A. 1973).

Accordingly, it is respectfully requested that the rejection of claims 8, 10, 21, 23, 32, 34, 44, and 46 under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird, be reconsidered and withdrawn.

35 U.S.C. § 103(a) Rejection

The rejection of claims 3, 4, 6, 16, 17, 19, 27, 28, 30, 39, 40, and 42 under 35 U.S.C. § 103(a), as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent No. 6,581,596 to Truitt ("Truitt"), is respectfully traversed based on the following.

As discussed above, Bird fails to disclose each and every element of independent claims 1, 13, 14, 26 and 37 from which claims 3, 4, 6, 16, 17, 19, 27, 28, 30, 39, 40, and 42 depend respectively. As such, these claims cannot be obvious in light of Bird. *Application of Glass*, 472 F.2d 1388 (C.C.P.A. 1973).

Accordingly, it is respectfully requested that the rejection of claims 3, 4, 6, 16, 17, 19, 27, 28, 30, 39, 40, and 42 under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent No. 6,581,596 to Truitt, be reconsidered and withdrawn.

35 U.S.C. § 103(a) Rejection

The rejection of claims 7, 20, 32, and 43 under 35 U.S.C. § 103(a), as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent No. 5,277,175 to Riggs et al. ("Riggs"), is respectfully traversed based on the following.

As discussed above, Bird fails to disclose each and every element of independent claims 1, 13, 14, 26 and 37 from which claims 7, 20, 32, and 43 depend respectively. As such, these claims cannot be obvious in light of Bird. *Application of Glass*, 472 F.2d 1388 (C.C.P.A. 1973).

Accordingly, it is respectfully requested that the rejection of claims 7, 20, 32, and 43 under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent No. 5,277,175 to Riggs et al., be reconsidered and withdrawn.

35 U.S.C. § 103(a) Rejection

The rejection of claims 5, 18, 29, and 41 under 35 U.S.C. § 103(a), as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent Publication No. 2003/0121517 A1 to McFarland, Jr. ("McFarland Publication"), is respectfully traversed based on the following.

As discussed above, Bird fails to disclose each and every element of independent claims 1, 13, 14, 26 and 37 from which claims 5, 18, 29, and 41 depend respectively. As such, these claims cannot be obvious in light of Bird. *Application of Glass*, 472 F.2d 1388 (C.C.P.A. 1973).

Accordingly, it is respectfully requested that the rejection of claims 5, 18, 29, and 41 under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent Publication No. 2003/0121517 A1 to McFarland, Jr.

35 U.S.C. § 103(a) Rejection

The rejection of claims 11, 12, 24, 25, 35, 36, 47, and 48 under 35 U.S.C. § 103(a), as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent Publication No. 2005/0172954 A1 to Smith ("Smith Publication"), is respectfully traversed based on the following.

As discussed above, Bird fails to disclose each and every element of independent claims 1, 13, 14, 26 and 37 from which claims 11, 12, 24, 25, 35, 36, 47, and 48 depend respectively. As such, these claims cannot be obvious in light of Bird. *Application of Glass*, 472 F.2d 1388 (C.C.P.A. 1973).

Accordingly, it is respectfully requested that the rejection of claims 11, 12, 24, 25, 35, 36, 47, and 48 under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,592,349 to Bird in view of U.S. Patent Publication No. 2005/0172954 A1 to Smith, be reconsidered and withdrawn.

35 U.S.C. § 112 Rejection

The rejection of claims 2 and 38 under the second paragraph of 35 U.S.C. § 112 as failing to set forth the metes and bounds of the claim, is respectfully traversed based on the following.

Applicant has amended claims 2 & 38. It is believed that the Examiner's rejection of these claims is now moot.

Accordingly, it is respectfully requested that the rejection of claims 2 and 38 under the second paragraph of 35 U.S.C. § 112 as failing to set forth the metes and bounds of the claim, be reconsidered and withdrawn.

CONCLUSION

Wherefore, in view of the foregoing amendments and remarks, this application is considered to be in condition for allowance, and an early reconsideration and a Notice of Allowance are earnestly solicited.

This Amendment does not increase the number of independent claims, does not increase the total number of claims, and does not present any multiple dependency claims. Accordingly, no fee based on the number or type of claims is currently due. However, if a fee, other than the issue fee, is due, please charge this fee to Hitchcock Evert LLP's Deposit Account No. 503374.

Application No. 10/666,428
Amendment dated November 9, 2006
Reply to Office Action of August 9, 2006

Any fee required by this document other than the issue fee, and not submitted herewith should be charged to Hitchcock Evert LLP's Deposit Account No. 503374. Any refund should be credited to the same account.

If an extension of time is required to enable this document to be timely filed and there is no separate Petition for Extension of Time filed herewith, this document is to be construed as also constituting a Petition for Extension of Time Under 37 C.F.R. § 1.136(a) for a period of time sufficient to enable this document to be timely filed.

Any other fee required for such Petition for Extension of Time and any other fee required by this document pursuant to 37 C.F.R. §§ 1.16 and 1.17, other than the issue fee, and not submitted herewith should be charged to Hitchcock Evert LLP's Deposit Account No. 503374. Any refund should be credited to the same account.

Respectfully submitted,

By: 

Nathanael G. Barnes
Registration No. 46,286
Attorney for Applicant

NGB/mhg
HITCHCOCK EVERT LLP
P.O. Box 131079
Dallas, Texas 75313-1709
Direct: (214) 953-1161
Facsimile: (214) 953-1121
November 9, 2006

MARKED-UP VERSION

CONTINUOUS HIGH-FREQUENCY OSCILLATION BREATHING TREATMENT APPARATUS

FIELD OF THE INVENTION

[0001] The invention relates to a therapeutic breathing device which delivers continuous high-frequency oscillation therapy during both inhalation and exhalation to facilitate the removal of mucus secretions from the lungs.

BACKGROUND OF THE INVENTION

[0002] Healthy people are able to clear mucus secretions from their lungs by means of bi-directional airflow and a system of tiny hairlike follicles called "mucociliary escalators." Airflow passing over the secretions creates shear forces that combine with the mucociliary escalators to transport mucus from the lower respiratory tract to upper airways. From there the secretions can be removed by coughing.

[0003] However, during illness a person's normal ability to remove secretions may become impaired. As the natural secretion clearance mechanism becomes more challenged, secretions may build up in the lungs, bronchial and tracheal passages creating a heightened potential for further exacerbation of illness. Retained mucus secretions in the warm, moist environment of the lungs create an excellent opportunity for the growth of bacteria. In addition, retained secretions may hinder the lungs' ability to exchange gas and increase the risk of pulmonary neoplasm. Keeping the lungs open and clear of secretions is integral to maintaining a healthy defense of the pulmonary system.

[0004] As the population ages, and the quality of air decreases, assaults on the respiratory system continue to rise. In addition to curable pulmonary infections, there are some 16 million people in the United States alone diagnosed with chronic lung disease, and it is estimated that an

additional 16 million cases go undiagnosed. Associated costs in both healthcare and lost production hours are staggering.

[0005] Because of the rising costs associated with pulmonary disease and the importance of keeping the lungs clear, clinicians and patients alike seek simple, inexpensive therapy devices that can enhance secretion mobilization. However, despite the variety of devices available, few show evidence of overall benefit.

[0006] In the late 1970's a Swedish anesthesiologist pioneered the use of "high-frequency ventilation" for life support by programming a ventilator to deliver 60 breaths per minute, or 1 hertz. Subsequently the application of high-frequency delivery of gas to the airways was found to show favorable results in mobilizing secretions, especially when combined with medicated aerosol. While exact mechanisms of this therapy are not fully understood, it is likely that, as the column of air in the airways is oscillated by the high-frequency pulses of gas, the viscosity of the mucus is reduced by the untangling of some of the larger molecule strands, such as DNA and F-actin, which tend to be present as a byproduct of infection. Additionally, the high-frequency, intermittent delivery of gas contributes to a bi-directional flow creating wind shear forces which, in turn, help to mobilize the secretions in a cephalad fashion. However, in spite of therapeutic promise, the vast majority of those in need of this therapy do not have access to it because current technology is too complex and, therefore, ultimately too expensive.

[0007] U.S. Pat Nos. 4,592,349, 4,805,613, 4,838,260, 4,930,501, 5,007,420, 5,116,088, 5,165,398, and 5,862,802 describe ventilators that combine high-frequency oscillation gas flow with aerosol. However, because these ventilators are designed primarily for life support, they connect to the patient via patient adapters that incorporate relatively complex mechanized valves that open and close between phasic shifts from inhalation to exhalation.

[0008] U.S. Pat No. 4,592,349 describes a "pneumatic clutching means" as an exhalation valve assembly with a venturi slidably mounted within in such a way as to move between open and closed positions. Although highly effective in delivering life-support ventilation, the sliding venturi patient adapter is too complex, bulky, and costly to manufacture to be included in a simple, inexpensive therapy device. The patient interface necessitates the fabrication of a number of moving parts made of a variety of materials. The resulting friction of the constant sliding between open and closed positions eventually fatigues valve components that must be replaced. Additionally, the sliding venturi patient interface requires critical dimensions that prevent a reduction in its size and weight.

[0009] Although an alternate embodiment of a patient adaptor to be used with the above devices described in U.S. Pat. No. 4,592,349 utilizes a fixed venturi, it, nonetheless, must incorporate or attach to a mechanical exhalation valve that opens and closes between inhalation and exhalation. This design, again, although effective in delivering life-support ventilation, renders the patient connector too complex and costly to be used in a simple, inexpensive breathing therapy device.

[0010] In addition to being expensive because of their complexity of manufacturing and maintenance, the devices currently capable of delivering high-frequency oscillatory therapy to the lungs are complicated and difficult to use. They require either significant training of the patient or a trained professional to administer the therapy. U.S. Pat No. 4,592,349, cited above, also describes a simpler version of these life-support ventilators which is specifically intended for therapeutic use. However, even this simpler, scaled-down version is designed with a mechanism to terminate the delivery of gas during exhalation, as well as adjustments for both

pressure and pulse frequency during a therapy session. This design renders the device both costly to manufacture and complex to use.

SUMMARY OF THE INVENTION

[0011] The present invention is a simple apparatus for delivering continuous high-frequency oscillation therapy to the lungs during both inhalation and exhalation in order to assist in mucus secretion clearance. It comprises a pressurized gas source, a pressure reduction regulator, a flow interrupter, a nebulizer, and a fixed, open-aperture, shrouded venturi within the patient interface.

[0012] Accordingly, an object of the present invention is to provide a continuous high-frequency oscillation breathing treatment device that can be manufactured simply and inexpensively.

[0013] Another object of the invention is to provide a continuous high-frequency oscillation breathing treatment device that is sufficiently simple to use so that it requires little or no training.

[0014] Another object of the present invention is to provide a continuous high-frequency oscillation breathing treatment device that delivers pulses to the patient and allows the patient to exhale into it without stacking successive volumes of gas in the airways.

[0015] Another object of the invention is to provide a continuous high-frequency oscillation breathing treatment device that will be simple and inexpensive to maintain.

[0016] Another object of the invention is to provide a continuous high-frequency oscillation breathing treatment device that maximizes safety during use.

[0017] Another object of the invention is to provide a continuous high-frequency oscillation breathing treatment device that is sufficiently small and lightweight enough to be conveniently transported.

BRIEF DESCRIPTIONS OF THE DRAWINGS

[0018] FIG. 1 is a schematic representation of the continuous high-frequency oscillation breathing therapy apparatus of present invention;

FIG. 2 is a cross sectional side view in more detail of a patient interface circuit for use with the continuous high-frequency oscillation breathing therapy apparatus of present invention;

FIG. 3 is a cross sectional top view in more detail of a patient interface circuit for use with the continuous high-frequency oscillation breathing therapy apparatus of present invention;

FIG. 4 is an alternate embodiment cross sectional side view of a patient interface circuit which includes within a means for interrupting positive gas flow for use with the breathing therapy apparatus of the present invention;

FIG. 5 is an alternate embodiment exploded sectional view of the aft apertures of the patient interface circuit with a means for their partial occlusion, and a means to prevent inadvertent complete occlusion of the apertures;

FIG. 6 is a schematic representation of an alternate embodiment of the continuous high-frequency oscillation breathing therapy apparatus of present invention; and

FIG. 7 is a top view of an alternate embodiment of the patient circuit of the continuous high-frequency oscillation breathing therapy apparatus of present invention is incorporated within a ventilator circuit.

[0019] Reference Numerals in Drawings

- | | |
|---|------------------------------|
| 1 | Source Gas |
| 2 | Source Gas Supply Tube |
| 3 | Pressure Reduction Regulator |

4	Tube
5	Connector Tee
6	Tube
7	Flow Interrupter
8	Tube
9	Circuit Connector
10	Circuit Tube
11	Breathing Head Assembly
12	Circumferential Communication Space
13	Injector Nozzle
14	Aft Apertures
15	Forward Apertures
16	Rear Flange Communication Ports
17	Venturi Tube
18	Mouthpiece
19	Mouthpiece Opening
20	Aerosol Entrainment Port
21	Nebulizer
22	Tube
23	Reducing Orifice
24	Circuit Connector
25	Circuit Tube
26	Forward Flange Communications Ports

27	Forward Flange Communications Ports
28	Forward Venturi Support Flange
29	Forward Venturi Support Flange
30	Rear Venturi Support Flange
31	Aperture Adjustment Collar
32	Aperture Adjustment Collar Holes
33	Safety Crowns
34	Timer
35	Patient Compliance Monitor
36	Reservoir Tee
37	Tube
38	Medicament Reservoir
39	Tube
40	Specified Gas Source
41	Inspiratory Gas Connector
42	RFID Transceiver
43	RFID Tag
44	Ventilator Circuit Inspiratory Limb
45	Ventilator Circuit Expiratory Limb
46	Ventilator Circuit Y
47	Ventilator Circuit Y Patient Connector
48	Evacuation Reservoir Tube
49	Evacuation Reservoir

DESCRIPTION OF A PREFERRED EMBODIMENT

[0020] FIG. 1 shows a schematic diagram of a continuous high-frequency oscillation breathing treatment apparatus comprising a source of pressurized gas attached to a source gas 1, a gas supply tube 2, a reduction regulator 3, a flow interrupter valve 7, and a patient interface circuit comprised of circuit tubes 10 and 25, a breathing head assembly 11 and a nebulizer 21. Source gas 1 connects to pressure reduction regulator 3 by means of a source gas supply tube 2. Pressure reduction regulator 3 is connected via small a bore (1/8" ID) tube 4 to connector tee 5. One end of connector tee 5 attaches to tube 22 and the other end of connector tee 5 attaches to tube 6.

[0021] A tube 22, which has within it a reducing orifice 23, connects by one end to connector tee 5 and by the other end to circuit connector 24. Circuit tube 25 connects by one end to circuit connector 24 and by the other end to nebulizer 21.

[0022] Tube 6 connects by one end to connector tee 5 and by the other end to flow interrupter valve 7, for example, a pneumatic "logic cell cartridge", model A50146, manufactured by Percussionaire Corp. The other end of flow interrupter valve 7 is connected to tube 8 which connects to circuit connector 9. Circuit connector 9 connects to one end of circuit tube 10, and the other end of circuit tube 10 connects to the rearmost end of breathing head assembly 11.

[0023] Located on top toward the rear of breathing head assembly 11 are aft apertures 14. Forward apertures 15 are positioned approximately three-fourths of the way toward the front of breathing head assembly 11. Mouthpiece 18 and mouthpiece opening 19 are at the front end of breathing head assembly 11. Nebulizer 21 is connected to aerosol entrainment port 20 located on the bottom toward the rear end of breathing head assembly 11.

[0024] FIG. 2 is a cross sectional side view in more detail of patient interface circuit comprising circuit tubes 10 and 25, breathing head assembly, mouthpiece 18, and nebulizer 21. Circuit tube 25 connects to the bottom of nebulizer 21, which, in turn, connects to aerosol entrainment port 20 located at the rearmost bottom portion of breathing head assembly 11. Circuit tube 10 connects to the rearmost end of breathing head assembly 11 by connecting directly to an injector nozzle 13 which is positioned in the rear portion of breathing head assembly 11.

[0025] In the rear portion of breathing head assembly 11, above injector nozzle 13 is at least one of aft apertures 14 which open the shell of breathing head assembly 11 to the ambient. Inside breathing head assembly 11 is mounted a venturi tube 17 which is anchored in the rear by the annular support of rear venturi support flange 30 and near the middle of breathing head 11 by two forward venturi support flanges 28 and 29 in such a manner that the shell of breathing head assembly 11 functions as a shroud for venturi tube 17. Rear venturi support flange 30 contains several rear flange communication ports 16 which are longitudinal holes that perforate it circumferentially allowing communication between both sides of flange 30. Likewise, forward venturi support flanges 28 and 29 are perforated circumferentially and longitudinally by several forward flange communication ports 26 and 27 allowing communication between both sides of each of flanges 28 and 29. On top, near the middle of breathing head assembly 11 is at least one of forward apertures 15 which open the interior of breathing head assembly 11 shell to atmosphere. The forward portion of venturi tube 17 is sufficiently separated from the sides of breathing head assembly 11 shell so as to allow a circumferential communication space 12 which completes a communication corridor which extends from the rearmost cavity of breathing head assembly 11 through mouthpiece 18 and mouthpiece opening 19.

[0026] FIG. 3 is a cross sectional top view in more detail of a patient interface circuit comprising circuit tubes 10 and 25, breathing head assembly 11, nebulizer 21, and mouthpiece 18. Circuit tube 25 connects to the bottom of nebulizer 21. Circuit tube 10 connects to the rearmost end of breathing head assembly 11 by connecting directly to injector nozzle 13 which is positioned in the rearmost portion of breathing head assembly 11. This top view shows placement of aft apertures 14 and forward apertures 15, which open shell of breathing head assembly 11 to the ambient.

[0027] Operation of the breathing treatment apparatus, pictured in Figs. 1, 2, and 3, begins by loading a predetermined liquid medicament into nebulizer 21 by first detaching it from aerosol entrainment port 20. After filled nebulizer 21 is reattached, therapy is initiated by turning on source gas 1, which may be a compressor within the device, or an external pressurized gas source such as air or oxygen. Gas travels through source gas supply tube 2 into pressure reduction regulator 3 whereby it is modulated to a suitable constant flow. Reduction regulator 3 can be pre-set at the factory to a desirable flow in order to maximize the simplicity of the therapy. The regulated gas then flows through tube 4 to connector tee 5 which splits the gas into two streams. One goes into tube 22 where it is further regulated by reducing orifice 23, and then continues to circuit connector 24. Circuit connector 24 connects circuit tube 25 which carries gas to the bottom of nebulizer 21. Nebulizer 21 converts the liquid medication into aerosol which enters into aerosol entrainment port 20, ushering the aerosol into the rear cavity of breathing head assembly 11.

[0028] Meanwhile, the other stream of gas that was split at connector tee 5 continues into tube 6 and travels to flow interrupter valve 7. Valve 7 chops the constant gas flow into high-frequency pulses by interrupting it at regular intervals so that the flow becomes divided into

substantially equal volumes, or pulses, at the rate of 1 to 15 hertz. Valve 7 can be pre-set at the factory to a predetermined rate to maximize the simplicity of the therapy. Because the flow is constant and the pulses are substantially equal, the resulting pulsatile pressure amplitude is substantially constant. That is to say that the difference between the lowest pressure and the highest pressure of each pulse is substantially equal.

[0029] The high-frequency flow then continues through circuit 8 to circuit connector 9. Circuit connector 9 connects circuit tube 10 which carries the gas to the rearmost portion of breathing head assembly 11. Here, the high-frequency pulses enter injector nozzle 13 which directs them into the rear opening of venturi tube 17.

[0030] The continuous high-frequency pulsatile flow enters into venturi tube 17 which may either amplify or attenuate it. As the flow enters venturi tube 17, given little or no resistance at mouthpiece opening 19, the flow is amplified. As the flow encounters the narrowing throat of venturi tube 17, its velocity increases. Additional gas then enters via aft aperture 14 by virtue of two processes. First, the increased velocity lowers surrounding pressures creating a vacuum effect, first described by Swiss mathematician Daniel Bernoulli in 1738, pulling in or entraining additional gas. Second, the friction between the high-speed molecules and the adjacent low-speed molecules has the effect of pulling the low-speed gas molecules into the stream of the high-speed gas.

[0031] In effect, ambient gas is pulled into the rear cavity of breathing head assembly 11 through aft aperture 14 and aerosol entrainment port 20. As the velocity of the gas increases, the volume of entrained gas increases, and, therefore, overall flow increases.

[0032] However, as resistance at mouthpiece opening 19 increases, the entrainment process is impeded and overall flow is attenuated. Velocity within the venturi decreases, and, in

turn, entrainment and flow both decrease. Thus, the device allows the patient to exhale back into it, and the device is provided with a built-in safety mechanism. As the patient exhales or airway compliance decreases, resistance downstream from the venturi tube increases. The resulting decrease in delivered flow also decreases pressure, thereby protecting the airways and allowing the patient to exhale.

[0033] The mixture of high-frequency pulsatile flow from injection nozzle 13, aerosol from port 20, and ambient air from aft entrainment apertures 14 continue through the lumen of venturi tube 17, exiting its forward opening into mouthpiece 18 and out mouthpiece opening 19 to the patient. The patient seals his or her lips around mouthpiece 18 and inhales the aerosolized pulses of gas, taking them deep into the lungs. The patient then exhales back into mouthpiece opening 19 as the therapy continues. The combination of aft apertures 14, forward apertures 15, rear flange communication ports 16, and forward flange communication ports 26 and 27 allow both ingress and egress of flow, serving both inhalation and exhalation without the need for complex mechanisms to open and close valves during the therapy.

[0034] As the patient continues the high-frequency oscillation breathing therapy, several things begin to happen. The medicated aerosol and the oscillation of the air column in the conducting airways help reduce viscosity of the secretions. The bi-level flow created by high-frequency intermittent delivery of gas begins to create wind shear forces. A small pulse enters the airways, and then the flow momentarily stops. During this pause, the pressure in the upper airways drops to zero. Small volumes of gas that were previously delivered into the airways now begin to exit, momentarily unencumbered by the zero-pressure in the upper airways. As these exiting volumes of gas increase in velocity they continually push secretions from small distal airways to the larger openings in the upper airways where they can be more easily removed.

[0035] Throughout the high-frequency oscillation therapy session, the intermittent positive-pressure pulses continue constantly as the patient inhales and exhales through mouthpiece opening 19. The exhaled breath travels from mouthpiece opening 19 into circumferential communication space 12 and exits forward apertures 15. Aft apertures 14 and forward apertures 15 are calibrated with flow interrupter 7 so that the patient is able to exhale back into mouthpiece opening 19 even as the high-frequency positive gas flow continues. This calibration allows ample opportunity for exhaled breath to escape in order to prevent the successive stacking of inhaled breaths in the airways.

[0036] FIG. 4 depicts an alternate embodiment cross sectional side view of a patient interface circuit which includes within a means for interrupting positive gas flow for use with the continuous high-frequency oscillation breathing therapy apparatus of the present invention. Flow interrupter valve 7 is attached directly to the rearmost portion of breathing head assembly 11.

[0037] As regulated gas is directed through circuit tube 10 it enters into flow interrupter valve 7. Flow interrupter valve 7 chops the flow into high-frequency intermittent pulses which then go directly into injector nozzle 13 and continue the process as described above. This embodiment allows most of the elements of the apparatus to be included within the patient interface circuit itself.

[0038] FIG. 5 presents an alternate embodiment exploded sectional view of aft apertures 14 of breathing head assembly 11 with an annular aperture adjustment collar 31 to provide a means for partially occluding apertures 14 in order to increase and decrease the ingress and egress of flow. Each of aperture adjustment collar holes 32 is surrounded by a safety crown 33 to prevent inadvertent complete occlusion.

[0039] Aperture adjustment collar 31 is slidably attached to breathing head assembly 11 adjacent to aft apertures 14 so that it can be axially adjusted. When aperture adjustment collar 31 is positioned so that aperture adjustment holes 32 align fully with aft apertures 14, maximum ingress and egress of flow is allowed. As aperture adjustment collar 31 is rotated so that aperture adjustment holes 32 begin to overlap aft apertures 14, effectively reducing the opening size of the apertures, ingress and egress of flow becomes more diminished. The peaks of safety crown 33 eliminate inadvertent complete occlusion of aperture adjustment collar holes 32 by preventing a finger or hand from sealing them.

[0040] The embodiment depicted in FIG. 5 is applicable to aft apertures 14, which may be designated as primary for ingress of flow, and forward apertures 15 (FIGS. 1,2,3, &4), which may be designated as primary for egress of flow.

[0041] FIG. 6 is a schematic diagram of an alternate embodiment that includes a number of additional features incorporated into the continuous high-frequency oscillation breathing treatment device. Timer 34 is connected to source gas 1, as is patient compliance monitor 35 and RFID transceiver 42. Reservoir tee 36 connects tube 37 to tube 22. Tube 37 connects by the other end to medicament reservoir 38. Medicament reservoir 38 is in communication with nebulizer 21 via tube 39. Specified gas source 40 connects to one end of inspiratory gas connector 41. The other end of inspiratory gas connector 41 connects to aft apertures 14. RFID tag 43 is embedded into a plastic wall of nebulizer 21. Evacuation reservoir 49 connects to forward apertures 15 by means of evacuation reservoir tube 48.

[0042] Timer 34 allows the clinician or the patient to pre-set a time for the treatment. At the end of the therapy session timer 34 can either turn off the apparatus by terminating source gas 1, or alarm to notify the patient that the treatment is over. Patient compliance monitor 35

logs use of the device in order to allow a clinician to determine whether or not the patient is utilizing the device. Medicament Reservoir 38 receives gas flow through tube 37, which is connected to tube 22 by reservoir tee 36. Medication is pumped from medicament reservoir 38 through tube 39 to nebulizer 21. This allows medication to be stored in a location remote from nebulizer 21, and medication can be continually pumped into nebulizer 21 as the therapy progresses.

[0043] Aft apertures 14 may be designated as primary for inspiration. In this case, the content of inspired gas can be controlled by connecting specified gas source 40 to aft apertures 14 by way of inspiratory gas connector 41. Forward apertures 15 may be designated as primary for exhalation. In this case, apertures 15 can be left open to the ambient or can be connected to evacuation reservoir 49. RFID (Radio Frequency Identification) transceiver 42, connected to source gas 1, can recognize identification information transmitted from RFID tag 43, embedded in nebulizer 21, to determine whether or not the component is compatible with the apparatus. RFID transceiver 42 can be programmed to prevent gas source 1 from being initiated if a component is incompatible.

[0044] FIG. 7 depicts a top-view perspective of an alternate embodiment of the continuous high-frequency oscillation apparatus that is incorporated into a ventilator breathing circuit. Ventilator circuit inspiratory limb 44 and ventilator circuit expiratory limb 45 are connected to ventilator circuit Y 46. Ventilator circuit Y 46 is in fluid communication with ventilator circuit Y patient connector 47. Mounted within ventilator circuit inspiratory limb 44 is breathing head assembly 11, which is connected to the continuous high-frequency oscillation apparatus by circuit tube 10, which is also mounted within ventilator circuit inspiratory limb 44.

[0045] The configuration presented in the alternate embodiment of FIG. 7 allows a treatment to be given to a patient connected to a ventilator without the need to disconnect the patient from the ventilator circuit.